MicroPort - Firehawk Rapamycin Target Eluting Coronary Stent

  Out-of-Stock 

Purchase at Moment

Payment After 3 Month

Quarterly repayment with the lowest fees Recharge every three months, 200 million tomman for each season.

Features:

Target Eluting Stent

China Made

Treatment of coronary artery stenosis or occlusion disease

 
Notify me when available

  • 0
  • Out stock
  • Free

Pay in installments

Choose your plan:

Current plan: 3Month

Description: 30+3

Down payment: $0.00 (25.00%)

Number of payments: 3

Tax: $0.00

Amount of payment: $0.00

Overpayment: $0.00

Total: $0.00

Current plan: Cash

Description: نقدی

Down payment: $0.00 (0.00%)

Number of payments: 1

Tax: $0.00

Amount of payment: $0.00

Overpayment: $0.00

Total: $0.00

Description

Firehawk Rapamycin Target Eluting Coronary Stent

Firehawk Rapamycin Target Eluting Coronary Stent System is the World's First and Only Target Eluting Stent (TES), which is the new generation product of Shanghai MicroPort Medical (Group) Co., Ltd. following the Firebird and Firebird2 stent to treat coronary artery stenosis or occlusion disease.

 

Features

  • Adopted the platform of TES Technology
  • Coating exposed area is only 5% of the stent surface
  • Drug in-vivo released over 90 days
  • Polymer fully absorbed in 9 months
  • Average Metal Coverage Rate14.0-16.1%
  • World's lowest drug dosage stent, with only 1/3 dosage versus similar products while achieving the same efficacy

 

SHANGHAI MICROPORT MEDICAL - Firehawk Rapamycin Target Eluting Coronary Stent



Reference : 0

Data sheet

  • MicroPort
  • China

Specific References

New product



Leave a comment about this product

Write your review

Write your review

MicroPort - Firehawk Rapamycin Target Eluting Coronary Stent

Write your review